CTOs on the Move


 
With iCAD`s technology, cancer has finally met its match. As a global medical technology leader providing innovative cancer detection and therapy solutions, our technologies empower clinicians worldwide with an arsenal of tools to detect cancer and stop it in its tracks – streamlining workflow, improving accuracy, and personalizing results like never before. The ProFound AI Breast Health Suite is the first, best, and only complete, triple-threat solution that combines cancer detection, density assessment, and risk evaluation – all designed to accelerate discovery and improve outcomes. Our leading-edge cancer detection solution, ProFound AI®, is clinically proven to find cancers earlier and ...
  • Number of Employees: 100-250
  • Annual Revenue: $10-50 Million
  • www.icadmed.com
  • 98 Spit Brook Road Suite 100
    Nashua, NH USA 03062
  • Phone: 603.882.5200

Executives

Name Title Contact Details

Funding

iCAD raised $12.5M on 04/28/2020
iCAD raised $22M on 03/03/2021

Similar Companies

Amerx Health Care Corporation

Amerx Health Care Corporation is a Clearwater, FL-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Precept

Precept is a Arden, NC-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

The Ohio Willow Wood Company

The Ohio Willow Wood Company is a Mount Sterling, OH-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Amulet Pharmaceutical

Amulet Pharmaceutical is a Halethorpe, MD-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Elucid

Elucid is a Boston-based medical technology company using uniquely interpretable and validated AI to provide physicians with a cost-effective means to optimize treatment decisions for patients with cardiovascular disease. Advanced clinical insight from Elucid equips physicians with critical information designed to enable precision medicine. Elucid is the first FDA-Cleared and CE-marked non-invasive software to quantify atherosclerotic plaque characteristics compared to histopathology, including Lipid Rich Necrotic Core. The company has published studies for its derivation of fractional flow reserve (FFRct) based on the vasodilative capacity of the vessel wall and estimation of coding and non-coding RNA transcripts (“Virtual Transcriptomics”). This unique information informs improved treatment decisions by physicians leading to better patient outcomes, improved quality of care, and reduced healthcare costs. The Elucid software is available for commercial use in the U.S. and Europe